Colorado Sets Precedent by Embracing Both Pharmaceutical and Natural Psychedelic Medicine Pathways

In a significant policy shift, Colorado has positioned itself as a leader in the emerging psychedelic medicine landscape by embracing both pharmaceutical and natural medicine approaches. Recent developments at the federal level, including an executive order by President Donald Trump to expedite federal review of psychedelic drugs for serious mental illness, have accelerated the timeline for these treatments. The Food and Drug Administration quickly followed by awarding national priority review vouchers to three organizations: Compass Pathways for psilocybin-assisted therapy in treatment-resistant depression, Usona Institute for psilocybin in major depressive disorder, and Otsuka for methylone in PTSD. These vouchers could reduce the FDA review process from up to a year down to just one or two months

Colorado’s Senate Bill 26-31, signed by Governor Jared Polis, ensures that once the Drug Enforcement Administration reschedules any FDA-approved Schedule I drug, state law will automatically align, enabling immediate legal pharmaceutical dispensing. Importantly, the bill maintains a clear distinction between pharmaceutical psychedelics and the natural medicine framework established under Proposition 122. This dual-pathway system preserves Colorado’s facilitator-led healing centers and community-based access, in contrast to other states that typically choose between medical or community models

Dr. Shannon Hughes, co-founder of Elemental Psychedelics, emphasized the significance of maintaining both access routes. "The pharmaceutical pathway and the natural medicine pathway are not competing rivers. They are tributaries of the same watershed," said Hughes. She warns that prioritizing pharmaceutical access at the expense of community-based programs would be a mistake, noting that each pathway serves unique patient needs and draws from different traditions of healing

The ongoing implementation of Proposition 122 is seen as critical for ensuring equitable access and high standards in facilitator training, licensing, and healing center regulation. Hughes urges state legislators and regulators to remain committed to the original voter mandate, stating, "The careful work of Prop. 122 implementation—facilitator licensing, healing center regulation, training standards, equitable access, and the ongoing rulemaking around whether and how ibogaine will be incorporated—is exactly the work that makes a wider path real." She also calls on practitioners to seek comprehensive training before administering these therapies, cautioning against treating psilocybin-assisted therapy as a standard pharmaceutical intervention

The broader impact of Colorado’s approach is already attracting national attention, as other states consider how to structure their own psychedelic policies. Hughes encourages public engagement in the forthcoming rulemaking processes, highlighting the importance of community input in shaping access to natural medicine. She concludes that, "The medicines are coming, faster than we expected. The question is whether we will meet them with the depth and care this moment asks of us, and whether we will keep faith with the wider path Coloradans already chose."

From the OG Lab newsroom perspective, Colorado’s embrace of both pharmaceutical and natural psychedelic medicine pathways sets a precedent that could influence national policy debates. This dual framework acknowledges the complexity of patient needs and the value of community-based healing, while also enabling rapid access to federally approved treatments. Industry observers will be watching closely to see how Colorado’s model affects access, regulatory standards, and the evolution of psychedelic therapies across the United States